全球類器官市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

全球類器官市場預計將從2025年的16.7億美元成長至2034年的76.8億美元，2026年至2034年的複合年成長率（CAGR）為18.47%。隨著研究人員擴大利用3D器官模型研究人類生物學、疾病機制、藥物反應和發育過程，該市場正在不斷擴張。類器官是實驗室培養的結構，可以複製器官和組織的特定特徵。與傳統的2D細胞培養相比，類器官能夠提供生物學上更優越的模型，這推動了其在製藥研發和學術研究機構的應用。精準醫療和先進生物建模投入的增加也促進了對類器官技術及相關培養系統的需求。

製藥公司正在探索利用類器官進行藥物篩檢、毒性評估、疾病建模和生物標記研究。根據所採用的技術，研究人員可以建構模擬腸道、大腦、肝臟和腎臟等組織以及其他生物系統的類器官。患者來源的類器官在個人化醫療研究中尤其重要，因為它們有助於研究個別生物反應。培養基、支架、成像、自動化和分析工具的改進，使得類器官的建構流程日益精細化和可重複。

對更貼近人類的研究模式和更有效率的藥物研發流程的需求日益成長，推動了類器官的未來發展前景。自動化和高通量篩檢可望進一步促進類器官在藥物研發中的實用化。與人工智慧和先進成像技術的融合，可以更深入分析類器官的行為和藥物反應。標準化仍然至關重要，因為實驗室間和模型間的差異會影響結果的可重複性。幹細胞生物學、組織工程和分析技術的持續進步有望進一步拓展類器官的應用範圍。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、阻礙因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：對主要市場參與企業的市場定位、產品系列、策略舉措和財務表現進行詳細評估。它提供了有關競爭趨勢和主要參與者所採取的策略的寶貴見解。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它結合歷史趨勢、當前市場狀況和定量分析，揭示未來發展趨勢。

區域分析：我們對主要地理區域的市場表現進行全面審查，以確定高成長領域和區域趨勢，從而更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，從而更有效地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球類器官市場：依來源分類

• 市場分析、洞察與預測
• 源自多功能細胞的類器官
• 成體幹細胞衍生的類器官
• 腫瘤來源的患者類器官

第5章：全球類器官市場：依器官類型分類

• 市場分析、洞察與預測
• 腸子
• 肝
• 腦
• 腎
• 肺
• 胰臟
• 心
• 其他器官類型

第6章 全球類器官市場：依應用分類

• 市場分析、洞察與預測
• 藥物發現與篩檢
• 疾病和毒理學建模
• 精準醫療與個人化醫療
• 再生醫學
• 類器官生物銀行服務
• 其他用途

第7章 全球類器官市場：依最終使用者分類

• 市場分析、洞察與預測
• 學術研究機構
• CRO 和 CDMO
• 醫院和診斷檢查室
• 製藥和生物技術公司

第8章 全球類器官市場：依技術分類

• 市場分析、洞察與預測
• 利用3D生物列印技術的類器官
• 人工智慧驅動的自動化平台
• 微流體晶片器官整合
• 利用支架進行3D培養
• 懸浮培養/無支架培養

第9章 全球類器官市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 中國
  • 日本
  • 韓國
  • 印度
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第10章 競爭格局

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第11章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Advanced BioMatrix Inc
  • ATCC
  • BICO Group AB
  • Cellesce Ltd
  • CN Bio Innovations Ltd
  • Corning Inc
  • Emulate Inc
  • Eppendorf SE
  • Greiner Bio-One International GmbH
  • HeartBeat.bio AG
  • Hubrecht Organoid Technology
  • InSphero AG
  • Lonza Group AG
  • Merck KGaA
  • MIMETAS BV
  • Miltenyi Biotec BV & Co. KG
  • QGel SA
  • Sartorius AG
  • STEMCELL Technologies Inc
  • Thermo Fisher Scientific Inc

The global organoids market size is expected to reach USD 7.68 Billion in 2034 from USD 1.67 Billion in 2025, growing at a CAGR of 18.47% during 2026-2034.This market is expanding as researchers increasingly use three-dimensional organoid models to study human biology, disease mechanisms, drug responses, and developmental processes. Organoids are laboratory-grown structures that can reproduce selected characteristics of organs or tissues. Their ability to provide more biologically representative models than some conventional two-dimensional cell cultures is encouraging adoption in pharmaceutical research and academic laboratories. Increasing investment in precision medicine and advanced biological modeling is also supporting demand for organoid technologies and associated culture systems.

Pharmaceutical companies are exploring organoids for drug screening, toxicity assessment, disease modeling, and biomarker research. Researchers can develop organoids representing tissues such as the intestine, brain, liver, kidney, and other biological systems, depending on the technology. Patient-derived organoids are particularly relevant to personalized research because they can help investigators study individual biological responses. Improvements in culture media, scaffolds, imaging, automation, and analytical tools are making organoid workflows increasingly sophisticated and reproducible.

Future prospects are supported by the growing need for human-relevant research models and more efficient drug-development processes. Automation and high-throughput screening could increase the practical use of organoids in pharmaceutical research. Integration with artificial intelligence and advanced imaging may enable more detailed analysis of organoid behavior and drug responses. Standardization remains an important requirement because variability between laboratories and models can affect reproducibility. Continued advances in stem-cell biology, tissue engineering, and analytical technologies are expected to broaden organoid applications.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Source

• Pluripotent Stem-Cell-Derived Organoids
• Adult Stem-Cell-Derived Organoids
• Tumor-Derived Patient Organoids

By Organ Type

• Intestinal
• Liver
• Brain
• Kidney
• Lung
• Pancreas
• Cardiac
• Other Organ Types

By Application

• Drug Discovery & Screening
• Disease & Toxicology Modelling
• Precision & Personalised Medicine
• Regenerative Medicine
• Organoid Biobanking Services
• Other Applications

By End User

• Academic & Research Institutes
• CROs & CDMOs
• Hospitals & Diagnostics Labs
• Pharmaceutical & Biotech Companies

By Technology

• 3-D Bioprinting-Assisted Organoids
• AI-Guided Automated Platforms
• Micro-Fluidic Organ-On-Chip Integrated
• Scaffold-Based 3-D Culture
• Suspension / Scaffold-Free Culture

COMPANIES PROFILED

• Advanced BioMatrix Inc., ATCC, BICO Group AB, Cellesce Ltd, CN Bio Innovations Ltd, Corning Inc., Emulate Inc., Eppendorf SE, Greiner Bio-One International GmbH, HeartBeat.bio AG, Hubrecht Organoid Technology, InSphero AG, Lonza Group AG, Merck KGaA, MIMETAS BV, Miltenyi Biotec B.V. & Co. KG, QGel SA, Sartorius AG, STEMCELL Technologies Inc., Thermo Fisher Scientific Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ORGANOIDS MARKET: BY SOURCE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Source
• 4.2. Pluripotent Stem-Cell-Derived Organoids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Adult Stem-Cell-Derived Organoids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Tumor-Derived Patient Organoids Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ORGANOIDS MARKET: BY ORGAN TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Organ Type
• 5.2. Intestinal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Liver Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Brain Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Kidney Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Lung Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Pancreas Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Cardiac Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Other Organ Types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ORGANOIDS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Drug Discovery & Screening Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Disease & Toxicology Modelling Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Precision & Personalised Medicine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Regenerative Medicine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Organoid Biobanking Services Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Other Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ORGANOIDS MARKET: BY END USER 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End User
• 7.2. Academic & Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. CROs & CDMOs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Hospitals & Diagnostics Labs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Pharmaceutical & Biotech Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ORGANOIDS MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Technology
• 8.2. 3-D Bioprinting-Assisted Organoids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. AI-Guided Automated Platforms Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Micro-Fluidic Organ-On-Chip Integrated Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.5. Scaffold-Based 3-D Culture Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.6. Suspension / Scaffold-Free Culture Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL ORGANOIDS MARKET: BY REGION 2022-2034 (USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Source
  • 9.2.2 By Organ Type
  • 9.2.3 By Application
  • 9.2.4 By End User
  • 9.2.5 By Technology
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Source
  • 9.3.2 By Organ Type
  • 9.3.3 By Application
  • 9.3.4 By End User
  • 9.3.5 By Technology
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Spain
  • 9.3.11 Russia
  • 9.3.12 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Source
  • 9.4.2 By Organ Type
  • 9.4.3 By Application
  • 9.4.4 By End User
  • 9.4.5 By Technology
  • 9.4.6 China
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 India
  • 9.4.10 Australia
  • 9.4.11 South East Asia
  • 9.4.12 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Source
  • 9.5.2 By Organ Type
  • 9.5.3 By Application
  • 9.5.4 By End User
  • 9.5.5 By Technology
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Source
  • 9.6.2 By Organ Type
  • 9.6.3 By Application
  • 9.6.4 By End User
  • 9.6.5 By Technology
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL ORGANOIDS INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Advanced BioMatrix Inc
  • 11.2.2 ATCC
  • 11.2.3 BICO Group AB
  • 11.2.4 Cellesce Ltd
  • 11.2.5 CN Bio Innovations Ltd
  • 11.2.6 Corning Inc
  • 11.2.7 Emulate Inc
  • 11.2.8 Eppendorf SE
  • 11.2.9 Greiner Bio-One International GmbH
  • 11.2.10 HeartBeat.bio AG
  • 11.2.11 Hubrecht Organoid Technology
  • 11.2.12 InSphero AG
  • 11.2.13 Lonza Group AG
  • 11.2.14 Merck KGaA
  • 11.2.15 MIMETAS BV
  • 11.2.16 Miltenyi Biotec B.V. & Co. KG
  • 11.2.17 QGel SA
  • 11.2.18 Sartorius AG
  • 11.2.19 STEMCELL Technologies Inc
  • 11.2.20 Thermo Fisher Scientific Inc